BCL6B抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: A549 cell lysate, Primary antibody: P09355(BCL6B Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 second    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09355(BCL6B Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The BCL6B antibody is a critical tool for studying the BCL6B protein, a transcriptional repressor encoded by the *BCL6B* gene. BCL6B, a paralogue of BCL6. belongs to the BTB/POZ zinc-finger protein family and regulates gene expression by recruiting chromatin-modifying complexes. It plays roles in immune regulation, cell differentiation, and apoptosis, particularly in lymphoid tissues. Dysregulation of BCL6B has been implicated in cancers, including B-cell lymphomas and solid tumors, where it may act as a tumor suppressor or oncogene depending on context.

The BCL6B antibody enables detection and quantification of BCL6B protein in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Its development typically involves immunizing hosts with peptide antigens derived from conserved BCL6B regions, followed by purification and validation for specificity (e.g., using knockout cell lines). Researchers utilize this antibody to explore BCL6B's role in disease mechanisms, therapeutic resistance, and its interplay with signaling pathways like NF-κB.

Challenges include cross-reactivity with BCL6 due to structural homology, necessitating rigorous validation. Optimizing protocols for tissue fixation and antigen retrieval is crucial for IHC applications. As BCL6B gains attention in precision oncology, its antibody remains vital for advancing biomarker discovery and targeted therapy research.